More recently, an extensive amount of research has been conducted to clarify the role of CXCR4/CXCL12 axis in human breast cancer and metastatic disease [1, 2, 10–12], suggesting that targeted therapies against CXCR4/CXCL12 axis may inhibit tumor growth. Here, CXCL12 is linked to metastatic neoplasm.